Why is P & G Health Ltd falling/rising?

As of 11-Sep, Procter & Gamble Health Ltd's stock price is currently at 6,360.50, reflecting an increase of 37.5 points, or 0.59%. The stock has shown a trend reversal, gaining after two consecutive days of decline. It is performing in line with its sector, and its delivery volume has increased by 29.5% compared to the five-day average, indicating rising investor participation. Over the past year, the stock has generated a return of 17.79%, outperforming the BSE500 in the last three years, one year, and three months. The company boasts high management efficiency with a return on equity (ROE) of 32.32% and has maintained a low debt-to-equity ratio, which supports its positive outlook. However, concerns about poor long-term growth persist, as net sales have grown at an annual rate of only 7.39% over the last five years.
In the broader market context, the stock's short-term performance has lagged behind the benchmark, with a 1-week return of -2.15% compared to the Sensex's +1.03%. Despite this, the stock has shown strong long-term performance, with a year-to-date return of 21.61% versus the benchmark's 4.36%. The high institutional holdings at 21.15% suggest that informed investors are backing the stock, which may provide some stability. However, the stock's valuation appears expensive with a price-to-book value of 19.7, and while it has generated a solid return over the past year, its profits have only risen by 39.3%, indicating potential valuation concerns.